Търсене на изпитвания

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 82 от 88

Активно (без набиране) Фаза 1/2

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Carcinoma

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Начало: 14.09.2021 Край: 01.06.2028 Възраст: 18–130 г. Лечение

Australia, Belgium, Brazil +13 AstraZeneca NCT04995523

Активно (без набиране) Фаза 3

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.

Начало: 12.09.2021 Край: 02.06.2027 Възраст: 18–130 г.

China, Germany, Israel +3 AstraZeneca NCT04765059

Активно (без набиране)

Supportive Oncology Care at Home Post-Discharge

Cancer

This study is evaluating if a program that involves remote monitoring and home-based care may improve the post-discharge care of recently hospitalized patients with advanced cancer. The Supportive Oncology Care at Home intervention consists of three key components: 1. Remote patient monitoring (e.g. patient-reported symptoms, home-monitored vital signs and body weight); 2. A Medically Home care model for symptom assessment, evaluation, and management (e.g. triggers for phone calls and visits to patients' homes to address and manage any concerning issues identified); 3. Structured communication with the oncology team to ensure continuity of care.

Начало: 19.08.2021 Край: 31.12.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT04637035

Активно (без набиране) Фаза 2

Combination Immunotherapy in Rare Cancers Under InvesTigation

Advanced Biliary Tract Cancer Neuroendocrine Tumors Female Reproductive System Neoplasm MSI-H Solid Malignant Tumor

The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded) 2. Biliary tract cancers: Intrahepatic cholangiocarcinoma and gallbladder carcinoma 3. Gynaecological malignancies: Ovarian clear cell carcinoma, uterine clear cell carcinoma, uterine/ovarian carcinosarcoma, uterine leiomyosarcoma and vaginal/vulva squamous cell carcinoma 4. Mismatch repair protein deficient (MSI-H) cancers (excluding colorectal carcinoma). The role of immunotherapy is being defined in more common cancer types, however because of their rarity, the efficacy of immunotherapy for these cancers is poorly defined. This protocol provides an important opportunity to establish whether the combination of nivolumab \& ipilimumab has efficacy in these cancers.

Начало: 03.08.2021 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, New Zealand Olivia Newton-John Cancer Research Institute NCT04969887

Активно (без набиране) Фаза 3

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Начало: 30.06.2021 Край: 01.09.2028 Възраст: 18–130 г. Лечение

Australia, Austria, Belgium +20 AstraZeneca NCT04964934

Активно (без набиране) Фаза 3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Advanced Colorectal Cancer Metastatic Colorectal Cancer

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Начало: 24.06.2021 Край: 30.01.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +26 Mirati Therapeutics Inc. NCT04793958

Активно (без набиране) Фаза 3

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Non-small Cell Lung Cancer NSCLC

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.

Начало: 08.06.2021 Край: 31.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +16 BeiGene NCT04746924

Активно (без набиране)

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NSCLC

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Начало: 10.05.2021 Край: 10.05.2027 Възраст: от 18 г.

Argentina, Australia, Belgium +21 Hoffmann-La Roche NCT04764188

Активно (без набиране) Фаза 2

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Hematopoietic and Lymphatic System Neoplasm Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma +34

This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.

Начало: 03.05.2021 Край: 30.06.2026 Възраст: 12–21 г. Лечение

Australia, Puerto Rico, United States National Cancer Institute (NCI) NCT04320888

Активно (без набиране) Фаза 3

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Lymphoma, Mantle-Cell

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.

Начало: 08.04.2021 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +18 Loxo Oncology, Inc. NCT04662255

Активно (без набиране) Фаза 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).

Начало: 18.03.2021 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, China +10 Jiangsu HengRui Medicine Co., Ltd. NCT04691804

Активно (без набиране) Фаза 2

Study of AZD2811 + Durvalumab in ES-SCLC

Small-Cell Lung Cancer

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Начало: 23.02.2021 Край: 01.12.2026 Възраст: 18–130 г.

Poland, South Korea, Spain +1 AstraZeneca NCT04745689

Активно (без набиране) Фаза 3

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Metastatic Non Small Cell Lung Cancer Advanced Non Small Cell Lung Cancer

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Начало: 23.02.2021 Край: 02.07.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +18 Mirati Therapeutics Inc. NCT04685135

Активно (без набиране) Фаза 2

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Начало: 02.02.2021 Край: 03.07.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +12 Daiichi Sankyo NCT04619004

Активно (без набиране) Фаза 3

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \[R-GemOx\], or bendamustine + rituximab \[BR\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously. Trial details include: * The trial duration will be up to 5 years after last participant is randomized. * All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death. * The estimated trial duration for an individual participant depends upon the treatment arm assigned: * Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events. * Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either: * R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or * BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.

Начало: 13.01.2021 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +19 Genmab NCT04628494

Активно (без набиране) Фаза 3

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.

Начало: 10.01.2021 Край: 15.09.2026 Възраст: от 18 г. Лечение

Argentina, Austria, Belgium +24 Merck Sharp & Dohme LLC NCT04634877

Активно (без набиране) Фаза 3

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Advanced/Metastatic Gastroesophageal Adenocarcinoma

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.

Начало: 30.12.2020 Край: 31.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Merck Sharp & Dohme LLC NCT04662710

Активно (без набиране) Фаза 2

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Urinary Bladder Neoplasms

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).

Начало: 18.12.2020 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Janssen Research & Development, LLC NCT04640623

Активно (без набиране) Фаза 3

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Urinary Bladder Neoplasms

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.

Начало: 07.12.2020 Край: 31.12.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Janssen Research & Development, LLC NCT04658862

Активно (без набиране) Фаза 3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Prostatic Neoplasms

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

Начало: 12.11.2020 Край: 27.08.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +15 Janssen Pharmaceutica N.V., Belgium NCT04557059

1 … 80 81 82 83 84 … 88